Thermo Fisher Scientific announced they will showcase their latest diagnostic innovations, recent regulatory milestones, and expanded capabilities at the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 26-30, 2026, in Anaheim, CA.

At booth 3501, they will present:

• The EXENT Solution, a fully integrated and automated mass spectrometry platform designed to aid in the diagnosis of multiple myeloma and related disorders. The system recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
• The Oncomine Dx Express Test (ODxET) on the Ion Torrent Genexus Dx Integrated Sequencer that received FDA approval in 2025 as a companion diagnostic for sunvozertinib (Zegfrovy) in non–small cell lung cancer and for tumor profiling in FFPE samples.
• Thermo Fisher’s EliA CTD 13 Screen, which received U.S. Food and Drug Administration (FDA) 510(k) clearance in June 2026, providing clinical laboratories with a new option for systemic connective tissue disease (CTD) testing.
• B·R·A·H·M·S biomarker testing portfolio, which improves early diagnosis and informs treatment plans for life-threatening illnesses, such as sepsis and preeclampsia.
• Thermo Fisher’s transplant diagnostics offerings, covering HLA typing and post-transplant monitoring patients, enhance a specialty diagnostics portfolio that spans from rare blood cancers and preeclampsia to autoimmune disease and transplant medicine.
• The Thermo Scientific TSQ Certis Triple Quadrupole Mass Spectrometer, launched in late 2025.
• The Applied Biosystems QuantStudio Dx Real-Time PCR System for molecular diagnostics workflows in clinical and public health laboratories.
• The Thermo Scientific B·R·A·H·M·S Fast Screen PLUS, which completes the company's prenatal screening solution by integrating biomarkers, instrumentation and clinically validated risk assessment algorithms into a connected digital platform designed to support standardized interpretation, consistent reporting and streamlined prenatal screening workflows.
• The LabLink360, featuring Sigma-metric analysis.

Additionally, Thermo Fisher experts and industry leaders will participate in several sessions during the conference, including:

• Automation of a complete and quantitative workflow for drugs of abuse in oral fluid – Darren Warnick Ph.D., Market Segment Leader, Regulated & Forensic Sciences, Hamilton, Tuesday, July 28, 11-11:30 a.m., Thermo Fisher Booth #3501
• New Frontiers for Pathogen Detection – Novel LC-MS Strategies Exploiting Omics-based Information to Characterize Microorganisms for Routine Clinical Practice – Troy Feener, MSc, Chief Operations Officer, Rapid Infection Diagnostics (RID), Wednesday, July 29, 11-11:30 a.m., Thermo Fisher Booth #3501
• Comparison of Human Immunoglobulins and Free Light Chain Testing Workflow and Efficiency on The Optilite Standalone Analyzer and An Integrated Chemistry Analyzer with Automation – Steve Stone, Managing Director, Argent, Wednesday, July 29, 11:30-12 p.m., Thermo Fisher Booth #3501
• Thermo Fisher Scientific Junior Innovators Challenge (JIC) Student Panel – Tina Liedtky, President of Transplant Diagnostics, Thermo Fisher, Tuesday, July 28, 1- 1:30 p.m., Thermo Fisher Booth #3501

Read Thermo Fisher's announcement on Businesswire for more information